KVUE Kenvue
FY2025 10-K
Kenvue (KVUE) filed its fiscal year 2025 10-K annual report with the SEC on Feb 20, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Global pure-play consumer health company with $15.1B FY2025 sales, focused on Self Care, Skin Health & Beauty, and Essential Health segments
- • New emphasis: Completed full independence from J&J by August 2023, exiting TSAs and building standalone systems and capabilities
Management Discussion & Analysis
- • Operating cash flow $2.2B in FY 2025, up $428M from $1.8B in FY 2024, driven by working capital timing in payables and receivables
- • Financing cash outflow $1.8B in FY 2025 vs $1.6B in FY 2024; included $1.58B dividends, $197M share repurchases, $750M debt repayment, $746M long-term notes issuance
Risk Factors
- • Regulatory risk from Section 368(a) Internal Revenue Code uncertainty; potential additional U.S. federal income taxes if Proposed Transaction fails to qualify as a “reorganization”
- • Geopolitical/macroeconomic risk with inflationary pressures and raw material cost volatility linked to military conflicts and tariffs
Financial SummaryXBRL
Revenue
$15.1B
Net Income
$1.5B
Gross Margin
58.1%
Operating Margin
16.0%
Net Margin
9.7%
ROE
13.7%
Total Assets
$27.1B
EPS (Diluted)
$0.76
Operating Cash Flow
$2.2B
Source: XBRL data from Kenvue FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Kenvue Annual Reports
Get deeper insights on Kenvue
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.